The FDA has announced it will no longer accept clinical trials that involve sending US patients cells from US to China for ...

MTPA's oral therapy Radicava (edaravone) has shown decreased functional decline and improved survival in long-term ALS trials ...

Degrees Pharmaceuticals has entered into a clinical study agreement with the Icahn School of Medicine at Mount Sinai in the ...

UK-based Monument Therapeutics has joined forces with the Foundation for the National Institutes of Health (FNIH), US, to ...

A recently published study provides an incentive to explore what specific aspects of vegetarianism are protective.

Biodexa has enrolled the initial two subjects in the Phase III Serenta study of eRapa, involving individuals with FAP.

Anocca has secured approximately Skr440m (around $46m) to primarily support the early-stage clinical trials of VIDAR-1.

BioAge Labs has dosed the first subject in the Phase I study of BGE-102, under development initially for treating obesity.

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

Reunion Neuroscience will be advancing its psychedelic therapy RE104 to a Phase III trial in post-partum depression (PPD) in ...

THL Partners has announced its agreement to purchase Headlands Research, a clinical trial sites network, from KKR-managed ...

Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.